

Regularly Scheduled Series
Hematology Oncology Grand Rounds
Department of Medicine/Section of Hematology/Oncology
University of Oklahoma Health Sciences Center



Course No. 22D12

Friday, January 7, 2022

8:00 – 9:15 a.m.

*** * * ZOOM PRESENTATION * * ***

Join Zoom Meeting

<https://zoom.us/j/92731544396?pwd=UTNwdFIBQ29BbUkvcGNPYlhxSE5qUT09>

Meeting ID: 927 3154 4396

Passcode: 32427799

One tap mobile: 16692192599

NOTE: The meeting host will admit you to the meeting no earlier than 15 minutes before the scheduled start time. If you login early then please wait for the host to admit you.

Attending a Zoom meeting:

If you have not yet attended a Zoom meeting then please visit this site (below) for information you will need:

<https://support.zoom.us/hc/en-us/articles/201362193-Joining-a-Meeting>

Title:

“Modern Radiotherapy for Mediastinal Lymphoma: Reducing Late Effects”

Presented by:



James Bates, MD

Assistant Professor, Department of Radiation Oncology
Winship Cancer Institute, Emory University

Professional Practice Gap: The utilization of radiotherapy in the treatment of lymphoma has declined over the past several decades, likely due to an increased concern for late toxicities caused by radiation. In this lecture, I will inform the audience on novel developments in the field to reduce the risk of these late effects to broaden the therapeutic ratio for radiotherapy in this disease.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to:

- 1) Describe the indications for radiotherapy in mediastinal lymphoma.
- 2) Distinguish changes in treatment planning, treatment techniques, and radiation doses for mediastinal lymphoma.
- 3) Evaluate the risk of late toxicity incurred by both radiotherapy and chemotherapy in the treatment of mediastinal lymphoma.

Accreditation Statement: The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable

Equal Opportunity Statement: The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link [ou.edu/reportingform](https://www.ou.edu/reportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit www.ou.edu/eoo.

Accommodation Statement: For accommodations on the basis of disability, call: 271-4022 ext. 48342.

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenter Disclosure: It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).

Commercial and In-Kind Support: This activity received no commercial or in-kind support.

Disclosure & Mitigation Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity's disclosure and mitigation information.

Role	First Name	Last Name	Nature of Relevant Financial Relationship		
			Ineligible Companies	What was received?	For what role?
Moderator/Planning Committee	Adam S.	Asch, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Committee	Raid M.	Aljumaily, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Committee	Rabia	Saleem, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Presenter	James	Bates, MD	Galera Therapeutics	Consulting Fee	Membership on Advisory Committee, Review Panel
<p>Presenter: Dr. Bates is no longer in a financial relationship with the ineligible company, but has been during the past 12 months. The conflict was resolved by Dr. Bates stating that the presentation does not have any relevance to the ineligible company and he will not be making clinical recommendations.</p>					
Course Director	Mohamad O.	Khawandanah, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Course Contact	Robin J.	Vinson	I have no financial relationships or affiliations with ineligible companies to disclose.		

**Section of Hematology/Oncology
University of Oklahoma Health Sciences Center**